gms | German Medical Science

55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

25. bis 28.04.2004, Köln

Differential antitumour effects of erlotinib (TarcevaTM, OSI-774), a novel epidermal growth factor receptor tyrosine kinase inhibitor, on human glioblastoma multiforme in a heterotopic in vivo model

Differentielle Antitumor-Effekte von erlotinib (TarcevaTM, OSI-774), einem neuartigen Inhibitor der Tyrosinkinase des epidermalen Wachstumsfaktorrezeptors, auf Glioblastoma multiforme in einem heterotopischen In-vivo-Modell

Meeting Abstract

  • corresponding author Marc-Eric Halatsch - Georg-August-Universität, Klinik und Poliklinik für Neurochirurgie, Göttingen
  • I. C. Bötefür - Klinik und Poliklinik für Neurologie, Freiburg
  • F. A.-Borhani - Georg-August-Universität, Klinik und Poliklinik für Neurochirurgie, Göttingen
  • V. I. Vougioukas - Abteilung Allgemeine Neurochirurgie, Freiburg
  • T. Efferth - Ruprecht-Karls-Universität, Zentrum für Molekulare Biologie, Heidelberg
  • U. Schmidt - Georg-August-Universität, Klinik und Poliklinik für Neurochirurgie, Göttingen
  • M. Buchfelder - Georg-August-Universität, Klinik und Poliklinik für Neurochirurgie, Göttingen

Deutsche Gesellschaft für Neurochirurgie. Ungarische Gesellschaft für Neurochirurgie. 55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie. Köln, 25.-28.04.2004. Düsseldorf, Köln: German Medical Science; 2004. DocMO.12.02

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dgnc2004/04dgnc0117.shtml

Published: April 23, 2004

© 2004 Halatsch et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective

We have previously demonstrated antiproliferative and antitumourigenic effects of erlotinib, a novel EGFR tyrosine kinase inhibitor, on glioblastoma multiforme (GBM) cell lines in vitro. The aim of the current study was to evaluate a potential therapeutic effect of erlotinib on GBM in a heterotopic in vivo model.

Methods

Athymic mice bearing established, palpable tumours derived from subcutaneous inoculation of cultured G-599GM or G-750GM human GBM cells (representing secondary or primary GBM, respectively) were treated with intraperitoneal injections of erlotinib once daily (50 mg/kg body weight in 200 μl 0.5% methyl cellulose) for 18 consecutive days. Correspondingly, control animals received mock intraperitoneal injections with 200 μl 0.5% methyl cellulose only. Tumour volumes were calculated based on regular tumour measurements across three diameters.

Results

Both control tumour growth and tumour response to treatment corresponded well to the proliferative behaviour in vitro in that G-750GM tumours grew faster and exhibited relative resistance against erlotinib-mediated growth inhibition while G-599GM tumours were characterized by delayed development and progression under control conditions as well as discernible regression in response to treatment. There was no compound-related mortality during the treatment period.

Conclusions

These results support our previous in vitro-based hypothesis that erlotinib may be a promising agent especially against secondary GBM. Further studies including larger sample collectives are strongly warranted.